ALZAMEND NEURO, INC. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/9db9777e-fe1d-45a7-bc93-ff89b5c9b75e/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-8.8M | 2025-05-01 – 2026-04-30 | evidence 0001214659-26-008832 |
| FY 2024 | $-4.5M | 2024-05-01 – 2025-04-30 | evidence 0001214659-25-010763 |
| FY 2023 | $-9.9M | 2023-05-01 – 2024-04-30 | evidence 0001214659-24-013191 |
| FY 2022 | $-14.9M | 2022-05-01 – 2023-04-30 | evidence 0001214659-23-010076 |
| FY 2021 | $-12.3M | 2021-05-01 – 2022-04-30 | evidence 0001214659-22-008985 |
| FY 2020 | $-5.0M | 2020-05-01 – 2021-04-30 | evidence 0001214659-21-007963 |
| FY 2019 | $-4.4M | 2019-05-01 – 2020-04-30 | evidence 0001214659-21-007963 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).